Table 1 Clinical characteristics, immunohistochemical and molecular markers available of patients with grade 1, 2 and 3A
N | Total | Mutated EZH2 in FFPE (n = 36) | Unmutated EZH2 | p-value | |
|---|---|---|---|---|---|
(n = 141) | in FFPE (n = 105) | ||||
Clinical characteristics at diagnosis, n (%) | |||||
Age at diagnosis, mean (range) | 141 | 62 (15–90) | 64 (42–90) | 62 (15–89) | 0.248 |
Sex | |||||
Female | 141 | 82 (58) | 23 (64) | 59 (56) | 0.441 |
Male | 59 (42) | 13 (36) | 46 (44) | ||
Histology | |||||
Grade 1, 2 | 131 | 87 (66) | 27 (77) | 68 (72) | 0.299 |
Grade 3A | 44 (34) | 8 (23) | 26 (28) | ||
Ki67 | 124 | ||||
Low | 55 (44) | 16 (29) | 39 (71) | 0.54 | |
Intermediate | 47 (38) | 12 (26) | 35 (74) | 0.84 | |
High | 22 (18) | 5 (23) | 17 (77) | 0.45 | |
Stage | |||||
I-II | 139 | 40 (29) | 7 (21) | 33 (33) | 0.204 |
III-IV | 99 (71) | 28 (79) | 71 (67) | ||
FLIPI risk categories | |||||
Low-Intermediate | 124 | 88 (71) | 22 (65) | 66 (73) | 0.379 |
High | 36 (29) | 12 (35) | 24 (27) | ||
Bulky mass | 140 | 36 (26) | 11 (31) | 25 (24) | 0.508 |
Extranodal | 140 | 34 (24) | 8 (22) | 26 (25) | 0.824 |
Bone narrow infiltration | 139 | 47 (34) | 13 (37) | 34 (33) | 0.682 |
B-symptoms | 140 | 39 (28) | 9 (25) | 30 (29) | 0.830 |